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A B S T R A C T
Rickettsia spp. can be found across the globe and cause disease of varying clinical severity, ranging from life-
threatening infections with widespread vasculitis to milder, more localized presentations. Vector and, to some
degree, reservoir are hematophagous arthropods, with most species harboured by ticks. In Denmark, rickettsiae
are known as a cause of imported travel-related infections, but are also found endemically in ticks across the
country. Data are, however, lacking on the geographical origin and clinical features of diagnosed cases.
In this study, we have examined the travel history and clinical features of two groups of patients; 1) hospital-
patients diagnosed with rickettsioses in the years 2010–2015 and 2) patients from primary health care (PHC)
centers in Denmark having demonstrated anti-rickettsia antibodies in the years 2012–2015. The patients were
identiﬁed using the Danish National Patient Registry (DNPR) and through the serological database at the State
Serum Institute, where the laboratory diagnosis of rickettsioses is currently centralized. Data were collected for
86 hospital patients and 26 PHC center patients by reviewing hospital medical records and performing telephone
interviews with PHC centers.
Of the hospital patients, 91% (78/86) had a history of international travel 14 days prior to symptom start,
with most having imported their infection from southern Africa, South Africa in particular (65%), and presenting
with a clinical picture most compatible with African tick-bite fever caused by R. africae. Only two patients
presented with a CRP > 100mg/L and no mortalities were reported. At the PHC centers, most patients pre-
sented with mild ﬂu-like symptoms and had an unknown (50%) or no history (19%) of international travel,
raising the possibility of endemic rickettsioses. In view of our ﬁndings, rickettsioses do not appear to constitute a
major public health problem in Denmark, with most cases being imported infections and potential endemic cases
presenting as mild infections.
1. Introduction
The Rickettsia genus encompasses small, Gram-negative, aerobic,
obligate intracellular, pleomorphic bacteria that can be transmitted to
humans via hematophagous arthropods such as ticks, ﬂeas, mites and
lice. Twenty-six diﬀerent species have so far been identiﬁed worldwide,
of which at least ﬁfteen are potentially pathogenic to humans (Parola
et al., 2013). They can be serotypically divided into the spotted fever
group (SFG) and the typhus group (TG) of which the SFG is the most
frequently encountered. The pathophysiology is characterized by in-
vasion and replication in vascular endothelial cells causing varying
degrees of vasculitis in small to medium-sized blood vessels and re-
sulting in symptoms such as fever, rash, headache, myalgia, arthralgia
and sometimes eschar (“tache noir”) (Raoult and Roux, 1997). Clinical
severity is associated with the underlying species ranging from poten-
tially fatal disease such as Rocky Mountain spotted fever caused by
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Rickettsia rickettsii to the more benign African tick-bite fever caused by
Rickettsia africae.
SFG rickettsiae are an important cause of imported travel-related
infections, but can also be found endemically in the Scandinavian
countries (Askling et al., 2009; Jensenius et al., 2003; Kantsø et al.,
2010; Nilsson et al., 1999a; O’Brien et al., 2001; Quarsten et al., 2015;
Skarphédinsson et al., 2007; Stensvold et al., 2015; Svendsen et al.,
2009; Wölfel, 2017). In Denmark, Rickettsia helvetica and Rickettsia
monacensis have been detected by PCR in Ixodes ricinus ticks (Kantsø
et al., 2010; Skarphédinsson et al., 2007; Stensvold et al., 2015;
Svendsen et al., 2009; Wölfel, 2017). Of these, R. helvetica is the most
prevalent SFG rickettsia and has been found in ticks all over the country
with one study by Svendsen et al. showing a prevalence of 13%, making
it one of the most common tick-borne organisms (Kantsø et al., 2010;
Skarphédinsson et al., 2007; Stensvold et al., 2015; Svendsen et al.,
2009). Despite this fact, data are lacking on the occurrence and clinical
features of both endemic and imported rickettsioses in Denmark.
In this study, we have reviewed the clinical features and travel
history of two groups of patients; 1) in-hospital patients diagnosed with
rickettsial disease and 2) primary health care (PHC) center patients
exhibiting anti-rickettsia antibodies. The aim was to elucidate the
clinical spectrum of infection in Danish patients aﬄicted by rick-
ettsioses and to examine the geographical origin of imported cases in
these two cohorts.
2. Materials and methods
2.1. Data sources for study cohorts
Personal identiﬁcation numbers of hospital patients were extracted
from the Danish National Patient Registry (DNPR). The DNPR, estab-
lished in 1977, records data on all patients discharged from non-psy-
chiatric hospitals. Since 1995 it has also included data on all visits to
outpatient departments and emergency clinics in Denmark (Lynge
et al., 2011). Diagnoses are coded by the attending physician according
to the International Classiﬁcation of Diseases, Tenth Revision [ICD-10].
From this registry we extracted personal identiﬁcation numbers of pa-
tients appointed a clinical diagnoses of rickettsiosis.
Personal identiﬁcation numbers of PHC center patients were ex-
tracted from the serological database at the State Serum Institute (SSI),
where the laboratory diagnosis of rickettsioses is currently centralized,
thus giving us access to serological data from across the country.
2.2. In-hospital patient cohort
The DNPR was searched for 15 ICD-10 codes relating to the diag-
nosis of rickettsiosis (Table A1 in Supplementary material), in the years
2010–2015. The search yielded 430 national records. Three university
hospitals were selected for data collection; Rigshospitalet in
Copenhagen, Hvidovre University Hospital in Hvidovre, a suburb to
Copenhagen, and Odense University Hospital in the city of Odense on
the island of Funen. These hospitals were chosen as they house major
departments of infectious diseases, diagnosing and treating a wide
variety of infectious diseases, both endemic and imported. In the years
2010–2015, a total of 120 patients had been appointed ICD-10 codes of
rickettsial disease at these hospitals, representing 28% of the national
total; 37 (31%) at Rigshospitalet, 16 (13%) at Hvidovre University
Hospital and 67 (56%) at Odense University Hospital. These patients
had their medical records reviewed by LFO and BBJ and were screened
for eligibility. Thirty-two patients were excluded as they were given
another diagnosis in their electronic medical records, despite being
appointed an ICD-10 code indicating rickettsioses. Another two patients
were excluded as their medical records were unavailable. In the end, a
total of 86 hospital patients were found to be eligible (Fig. 1). The
clinical manifestations and travel history of these patients were used in
the ﬁnal analysis. A cut-oﬀ of 14 days prior to symptom start was
chosen for the travel history as it corresponds to the maximum in-
cubation period of most rickettsial diseases.
2.3. PHC center patient cohort
The SSI serological database was searched for sera submitted from
PHC centers and tested for anti-rickettsia antibodies in the years
2012–2015. A total of 293 samples were identiﬁed, of which 94 (32%)
exhibited anti-rickettsia antibodies. Seventy-nine individual patients
could be identiﬁed, after duplicate samples had been removed. The
PHC centers having requested the serological analysis were contacted
using telephone interviews and inquired about the patient’s clinical
manifestations and any mention of travel history in the corresponding
medical records. In case no travel history was mentioned in the medical
records, it was noted as “unknown”. To mitigate recall bias, we started
with the PHC centers that had most recently requested the analysis and
then continued in a consecutive manner until 2012. Interviews were
conducted by a medical student and followed a strict questionnaire
(Fig. B1 in Supplementary material). In the event that data could not be
directly provided over the telephone, they were faxed over to SSI.
Forty-nine patients were excluded due to the PHC centers failing to
provide relevant data and four patients were excluded due to stationary
or diminishing IgM without IgG seroconversion on convalescent sera. In
the end, data were provided for 26 patients from 25 PHC centers
(Fig. 2). Fourteen of these patients had also been tested for antibodies
against Borrelia burgdorferi sensu lato, Anaplasma phagocytophilum,
Bartonella spp. and Francisella tularensis. Antibodies against one of these
pathogens were detected in four patients. However, as three of them
had high IgG titer values against SFG rickettsiae (1:512, 1:1024,
1:1024), prior exposure to rickettsiae was still very likely. The fourth
patient was asymptomatic and exhibited IgM antibodies against SFG
rickettsia (1:128) and IgG antibodies against Anaplasma phagocyto-
philum. The antibody titers of the included patients are presented in
Table 1.
2.4. Laboratory diagnosis of rickettsiosis
2.4.1. Serology
Serological analysis at SSI is performed using a commercially
available indirect immunoﬂuorescense assay (IFA) produced by Focus
Diagnostics (IF0100G, Rickettsia IFA IgG; Focus Diagnostics, Inc.,
Cypress, CA, USA). The assay exploits the cross-reactivity of antibodies
within the SFG rickettsiae and TG rickettsiae and uses antigens from R.
rickettsii (RR) and Rickettsia typhi (RT) to discriminate between these
two groups. The assay has been used for several years at SSI and has
been shown to detect antibodies against both R. africae (Johansen and
Thybo, 2011) and R. helvetica (unpublished data). A titer of 1:64 or
above is considered positive for IgM. For IgG, the same applies for a
titer of 1:512 or above. Both the IgG and IgM cut-oﬀ values are based on
Danish healthy blood donors to achieve a speciﬁcity of 95%. This has
resulted in a slight increase of the manufacturer’s cut-oﬀ value for IgG
(Kantsø et al., 2009). The IFA IgG kit has been evaluated for cross-
reactivity with other bacteria using a panel of 80 sera from patients
with antibodies against organisms that might cross-react with rick-
ettsiae including Salmonella spp., Campylobacter jejuni, Helicobacter py-
lori, Coxiella burnetii, Mycoplasma pneumonia, Chlamydophila pneumo-
niae, Bartonella henselae and Borrelia burgdorferi sensu lato. Cross-
reactivity was reduced considerably using the modiﬁed cut-oﬀ levels
with none of the examined samples displaying reactivity at an IgG titer
of 1:512 or above. Furthermore, neither the IFA IgM nor the IgG kits
have during the years of routine use and using the current cut-oﬀ levels
displayed any signiﬁcant cross-reactivity with other tick-borne patho-
gens such as Anaplasma phagocytophilum, Borrelia burgdorferi sensu lato,
Bartonella spp. and Francisella tularensis. To further prevent cross-re-
activity, all samples underwent rheumafactor adsorption, prior to IgM
determination.
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2.4.2. PCR
A real-time PCR with genus-speciﬁc primers (CS-F and CS-R) was
used to amplify a 74-bp fragment of the R. rickettsii citrate synthase
(gltA) gene as previously described (Stenos et al., 2005).
3. Results and discussion
We found that rickettsioses do not appear to pose a major public
health problem in Denmark, with most of the hospital patients pre-
senting with mild infections caused by SFG rickettsiae. Only two of the
hospital patients presented with a considerable inﬂammatory response
as reﬂected in an elevated CRP over 100mg/L. Treatment of choice was
doxycycline in 90% (77/86) of the hospital cases, with the remaining
cases receiving no treatment at all (8/86) or azithromycin (in a preg-
nant woman). No fatalities were reported and all hospital patients re-
covered from their infections. Of the 79 PHC patients exhibiting anti-
rickettsia antibodies in the years 2012–2015, clinical data were
obtained for 26 (33%), none of whom presented with severe or acute
life-threatening symptoms.
Considering a Danish population of 5,500,000, an incidence of 1.3/
100,000 per year can be estimated for the hospital cases, most of which
are imported. For the PHC centers, an incidence of 0.8/100,000 per
year can be estimated, assuming that the number of patients with
rickettsiosis and no detectable antibody reactivity at the time of diag-
nosis, is the same size as those who are seropositive. Combined, these
two estimates give an estimated national incidence of around 2.0/
100,000 per year (Appendix C in Supplementary material). The travel
history and clinical manifestations of both cohorts are presented in
Figs. 3 and 4 and Tables 2 and 3.
3.1. Hospital
3.1.1. Imported rickettsial infections
Almost all (91%) of the hospital patients had a travel history outside
Fig. 1. Inclusion process for the hospital cohort. HH:
Hvidovre Hospital. OUH: Odense University
Hospital. RH: Rigshospitalet.
Fig. 2. Inclusion process for the PHC center cohort.
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of Denmark with the incidence slightly peaking in late winter and early
spring (January through April). Cases were, however, reported
throughout the whole year (Table 4). Fever/chills and eschar(s) were
the most common clinical manifestations seen in 84% (72/86) and 57%
(49/86) of the patients respectively. The diagnosis was most often made
on clinical grounds alone (24/86) in patients with characteristic clinical
manifestations, such as eschar(s), and a relevant travel history. Rick-
ettsia DNA was detected using PCR in eleven patients, with all samples
coming from swabs or skin biopsies except for one blood specimen. Of
the 15 patients who also had convalescent sera submitted for analysis,
only ﬁve demonstrated IgG seroconversion or a greater than two-fold
dilution rise in titer.
A key ﬁnding was that a signiﬁcant majority of the hospital patients
had a travel history to southern Africa, South Africa in particular
(65%), and a clinical picture compatible with African tick-bite fever
caused by R. africae. Despite other SFG rickettsiae such as Rickettsia
conorii, Rickettsia aeschlimannii and Rickettsia mongolitimonae being
present in this region, 16% (14/86) of the patients had multiple es-
chars, a feature characteristic of African tick-bite fever, and 33% (28/
86) had visited Krueger National Park for safari or game hunting, a
known risk factor for this type of travel-related rickettsiosis (Parola,
2006; Pretorius and Birtles, 2004, 2002). All except two of the patients
presenting with multiple eschars had visited South Africa with the
remaining having visited Zimbabwe and Kenya, both endemic for R.
africae. None of these patients presented with severe infection in-
dicative of the more virulent Mediterranean spotted fever caused by R.
conorii (Pretorius et al., 2004; Raoult et al., 1986). Only one patient in
the hospital cohort was diagnosed with TG rickettsiosis (murine ty-
phus), following a visit to Tunisia, but underwent spontaneous remis-
sion without treatment. A similar distribution of rickettsioses has been
reported in several single-center and multi-center studies, with African
tick-bite fever being the most common rickettsial infection in returned
travelers (Freedman et al., 2006; Jelinek and Löscher, 2001; Jensenius
et al., 2003, 2002)
3.1.2. Endemic rickettsial infections
Despite eight of the hospital patients denying any recent travel
history in their medical records, thereby raising the possibility of an
endemic rickettsiosis, only one of them demonstrated convincing la-
boratory evidence of infection with a greater than two-fold dilution rise
in titer and IgG seroconversion in the convalescent sera. This low
number of possible endemic rickettsioses in the hospital cohort is in line
with several other studies, reporting asymptomatic seroconversion or
mild, self-limiting disease during infection with R. helvetica, likely
perceived as too mild for hospital referral by many primary care phy-
sicians (Fournier et al., 2004, 2000; Lindblom et al., 2016; Phongmany
Table 1
Antibody titers against Rickettsia spp. in the hospital (a) and PHC center (b) cohorts. Serology was requested for 54 (63%) in-hospital patients. Of these, 31 displayed initial antibody
reactivity against Rickettsia spp. Nineteen of the hospital patients displayed solely RR IgM, ﬁve had RR IgG and the remaining had some constellation of two or more types of antibodies.
Of the 26 PHC center patients, 17 patients displayed solely RR IgM, one displayed RR IgG alone and eight had some constellation of two or more types of antibodies. The cut-oﬀs used
were 1:64 for IgM and 1:512 for IgG. All sera were analyzed at SSI. RR: R. rickettsii. RT: R. typhi.
1:64 1:128 1:256 1:512 1:1024 1:2048 1:4096 1:8000 1:16000 1:32000
a.
RR IgM 5 10 3 3 1 1 0 0 1 1
RR IgG – – – 2 2 0 2 1 0 0
RT IgM 0 1 0 0 0 0 0 0 1 0
RT IgG – – – 3 0 0 1 0 0 0
b.
RR IgM 4 11 4 1 2 1 0 0 0 0
RR IgG – – – 1 2 3 1 1 0 0
RT IgM 1 0 1 0 0 0 0 0 0 0
RT IgG – – – 1 1 0 0 0 0 0
Fig. 3. Travel history of hospital patients (n= 86) 14 days prior to symptom start. Most patients (65%) had visited South Africa. Eight patients denied international travel. Other
destinations included: Kenya, Tanzania, Zimbabwe, Ethiopia, Swaziland, Indonesia, Vietnam, Egypt, Tunisia, Nepal, Turkey, Panama, Czech Republic, Italy, Hungary, South Korea, Laos,
Thailand, and The Dominican Republic.
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et al., 2006). Serious infections with R. helvetica have been described by
a Swedish research group (Nilsson, 2009; Nilsson et al., 2011, 2010,
1999b). However, such reports are scarce and have, so far, not de-
scribed cases in other geographical locations, outside of Sweden, where
R. helvetica is also endemic in ticks.
3.2. PHC centers
For the PHC centers, only eight patients (31%) exhibiting anti-
rickettsia antibodies had international travel mentioned in their med-
ical records. Data on travel history for most patients (50%) was absent
and ﬁve patients (19%) denied recent international travel in their
medical records, again raising the possibility of endemic rickettsiosis.
This is, however, impossible to establish with certainty as only ﬁve of
the PHC patients had convalescent sera examined for antibodies of
which only one, after a trip to Africa, demonstrated a greater than two-
fold dilution rise in titer.
All PHC cohort patients presented with relatively mild disease, with
the most frequently reported clinical indication for requesting ser-
ological analysis being a witnessed tick or insect bite (38%) followed by
fever/chills (23%) and headache (19%). One of the patients was
asymptomatic, but was worried about having been infected with a tick-
borne pathogen following a tick bite and wanted to be tested to ease his
mind. Another one was asymptomatic, apart from the presence of an
erythema migrans lesion. Use of serology in such patients, diminishes
the positive predictive value and should be avoided. Five patients
Fig. 4. Travel history of PHC center patients (n= 26). Half of all patients had an unknown travel history as it was not commented upon in the medical records. For the rest of the patients,
most (ﬁve) had stayed in Denmark. Four patients had visited sub-Saharan Africa (South Africa, Tanzania and Malawi). Other destinations included: Guatemala, Nepal and Sweden. One
patient had visited an unspeciﬁed country in Africa.
Table 2
The most common clinical manifestations of patients diagnosed with rickettsiosis at hospitals.
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(19%) presented with “ﬂu-like symptoms”, an amalgamate of several
symptoms, of which the precise composition is subjective which is why
we have chosen to have this complex as a separate entity. Whether
symptoms such as fever/chills, headache or myalgia should be put
under this term could be discussed. Only two patients at the PHC
centers, both of whom had recently visited South Africa, were tested
due to the presence of an eschar. However, an unspeciﬁed skin ulcer
was present in one other patient, with no recorded history of interna-
tional travel, and could potentially represent a true eschar.
3.3. Strengths and limitations
This is the ﬁrst overview of the clinical manifestations and travel
history of patients with rickettsioses in Denmark, with most prior pa-
pers consisting of case reports and a short epidemiological report from
2012 (Johansen and Thybo, 2011; Kibsgaard et al., 2012a, 2012b;
Madsen et al., 2004; Nielsen et al., 2004). Contrary to previous papers,
we have included both hospital and PHC center patients, painting a
more complete picture of the burden of rickettsial infections. There are,
however, several weaknesses in this study, which are important to
address.
First of all, the analyzed data constitute only a small percentage of
Danish PHC patients suspected of rickettsioses as these patients had all
been chosen based on a positive serology and clinical data were only
provided for 33%. Basing the population solely on patients demon-
strating anti-rickettsia antibodies also carries the risk of under-
estimating the number of patients aﬄicted by rickettsioses with a weak
or delayed antibody response as well as patients diagnosed on clinical
grounds alone or using solely PCR (Fournier et al., 2002). However, as
only six PHC patients demonstrated a positive PCR analysis in the years
2012–2015, three of whom had visited South Africa, this latter concern
does not seem to be a major problem.
Furthermore, it is important to remember that, especially IgM an-
tibodies, have a tendency to cross-react and the possibility that some of
the patients could potentially have been infected with some other or-
ganism cannot be ruled out. Two-hundred and seventy-nine sera with
detectable anti-rickettsia antibodies were, in the years 2008–2015, also
tested for Borrelia burgdorferi sensu lato, Anaplasma phagocytophilum,
Bartonella spp. and Francisella tularensis. Of these, 72 (26%) displayed
antibodies against one other tick-borne organism and 10 (4%) exhibited
antibody reactivity against two other bacteria (unpublished data).
Whether this was due to cross-reactivity, prior exposure or co-infection
is not known.
Lastly, only ﬁve of the PHC center patients were followed-up with
convalescent samples making the diagnosis less certain in many cases,
especially in patients presenting with nonspeciﬁc symptoms. This is
especially problematic when attempting to diagnose infections caused
by the endemic R. helvetica which often lack a rash or the characteristic
Table 3
Clinical indications for requesting Rickettsia serology at PHC centers in Denmark.
Table 4
Seasonality of rickettsioses at Danish hospitals.
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eschar (Fournier et al., 2004; Phongmany et al., 2006). However, given
the high speciﬁcity of the serological assay used (95% for both IgM and
IgG), prior exposure to Rickettsia spp. is still probable in these patients.
4. Conclusion
Rickettsioses in Denmark most often present as mild infections.
Among hospital patients, imported infections are the most common,
with South Africa in particular dominating as the destination of choice
for travelers with rickettsiosis returning to Denmark, most of whom
have presumably been infected with African tick-bite fever caused by R.
africae. The diagnosis is most often made on clinical grounds alone with
a majority of patients presenting with a characteristic eschar and a
relevant travel history to South Africa in the winter and early spring
months. Only one in-hospital patient presenting with mild symptoms
had convincing evidence of having acquired the infection in
Scandinavia
Among patients who tested positive for anti-rickettsia antibodies at
PHC centers, 19% had no history of international travel and 50% had
no mention of travel history in the medical records. These patients most
often presented with mild, nonspeciﬁc ﬂu-like symptoms and only
rarely presented with cutaneous manifestations such as rash or eschar.
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